title: Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
abstract: OBJECTIVE
  Alterations in one-carbon metabolism (OCM) have been repeatedly reported in schizophrenia. However, there is a scarcity of studies addressing the effects of antipsychotics on selected OCM markers in schizophrenia and provided results are inconsistent.
  
  
  METHODS
  We recruited 39 first-episode schizophrenia (FES) patients and determined serum profile of total homocysteine (tHcy), folate, vitamin B12, lipoproteins and glucose at baseline and after 12 weeks of treatment with second-generation antipsychotics (SGA) including olanzapine and risperidone in monotherapy.
  
  
  RESULTS
  After 12 weeks of treatment, all patients had significantly higher body mass index (BMI), serum levels of total cholesterol (TC), low-density lipoproteins (LDL), triglycerides (TG) and tHcy together with significantly lower levels of folate and vitamin B12. The analysis of differences between SGA revealed the same biochemical alterations in patients treated with olanzapine as in the whole group, while those receiving risperidone had no statistically significant changes in serum folate, vitamin B12 and TG. There was a significantly higher increase in BMI and TC in patients treated with olanzapine in comparison with those treated with risperidone. Patients receiving olanzapine had a higher decrease in vitamin B12 than those assigned to the treatment with risperidone. Changes in folate, vitamin B12, tHcy and TC levels were significant only in males, even after Bonferroni correction. Multiple regression analysis revealed that changes in tHcy levels are associated with gender and baseline metabolic parameters (BMI, glucose, TC, LDL and HDL) but not with selected SGA.
  
  
  CONCLUSIONS
  These results indicate that SGA may influence OCM, especially in first-episode schizophrenia (FES) males.
authors.affiliation: Department of Psychiatry, Wroclaw Medical University, 10 Pasteur Street, 50-367, Wroclaw, Poland, mblazej@interia.eu.
authors.forename: Błażej
authors.initials: B
authors.lastname: Misiak
authors.forename: Dorota
authors.initials: D
authors.lastname: Frydecka
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Łaczmański
authors.forename: Ryszard
authors.initials: R
authors.lastname: Ślęzak
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kiejna
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002244:Carbon / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D005260:Female; D005492:Folic Acid / Q000097:blood; D006710:Homocysteine / Q000097:blood; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000139:chemically induced / Q000188:drug therapy; D000077152:Olanzapine; D018967:Risperidone / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D012737:Sex Factors; D014280:Triglycerides / Q000097:blood; D014805:Vitamin B 12 / Q000097:blood; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D014280:Triglycerides; D006710:Homocysteine; D001569:Benzodiazepines; D002244:Carbon; D005492:Folic Acid; D002784:Cholesterol; D018967:Risperidone; D000077152:Olanzapine; D014805:Vitamin B 12